BridgeBio Oncology Therapeutics (BBOT) Capital Expenditures (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at $24000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 22.58% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273000.0 (changed N/A YoY) and the FY2025 annual result came in at $606000.0, up 1136.73% from the prior year.
• Capital Expenditures eased to $24000.0 in Q1 2026 per BBOT's latest filing, from $208000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $208000.0 in Q4 2025 and troughed at $10000.0 in Q4 2024.
• A 3-year average of $68250.0 and a median of $27500.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures jumped 1980.0% in 2025, then retreated 22.58% in 2026.
• Over 3 years, Capital Expenditures stood at $10000.0 in 2024, then surged by 1980.0% to $208000.0 in 2025, then sank by 88.46% to $24000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $24000.0, $208000.0, and $31000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.